Compare IDYA & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | DAC |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2019 | 2006 |
| Metric | IDYA | DAC |
|---|---|---|
| Price | $28.22 | $129.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | $52.86 | ★ $112.50 |
| AVG Volume (30 Days) | ★ 676.7K | 81.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 3.00% |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.05 | N/A |
| P/E Ratio | ★ N/A | $4.01 |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $20.47 | $83.56 |
| 52 Week High | $39.28 | $135.21 |
| Indicator | IDYA | DAC |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 55.38 |
| Support Level | $27.66 | $92.03 |
| Resistance Level | $29.74 | $135.00 |
| Average True Range (ATR) | 1.05 | 3.99 |
| MACD | 0.04 | -0.84 |
| Stochastic Oscillator | 22.94 | 55.49 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.